Form 4: Cytokinetics EVP Fady Ibraham Malik Executes Stock Options and Sells Shares
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on October 15, 2024.
Summary
- On October 15, 2024, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics Inc., executed a transaction involving the company's stock.
- Malik exercised non-qualified stock options to acquire 5,300 shares of common stock at a price of $7.96 per share.
- Simultaneously, Malik sold 5,300 shares at $54.18 and 2,000 shares at $54.20.
- Following these transactions, Malik directly owns 116,920 shares of Cytokinetics Inc.
- Malik also owns 21,200 non-qualified stock options.
Sentiment
Score: 5
Explanation: Neutral. This is a standard Form 4 filing, indicating insider transactions. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This is a routine disclosure of insider transactions. It is common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 03/26/2015 | Date the non-qualified stock options became exercisable |
| 02/26/2025 | Expiration date of the non-qualified stock options |
| 10/15/2024 | Date of the stock option exercise and stock sales |
| 10/16/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.